Shreya Chablaney

Shreya Chablaney

Auto-generated profile, based on publicly available information

Shreya Chablaney

Icahn School of Medicine at Mount Sinai, New York, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Open access
DFDavid M. Faleck
David M. Faleck
AWAdam Winters
Adam Winters
SCShreya Chablaney
Shreya Chablaney
PSPreeti Shashi
Preeti Shashi
JMJoseph Meserve
Joseph Meserve
RURyan Ungaro
Ryan Ungaro
Patients with Crohn's disease (CD), but not ulcerative colitis (UC), of shorter duration have higher rates of response to tumor necrosis factor (TNF) antagonists than patients with longer disease duration. Little is known about the association between disease duration and response to other biologic agents. We aimed to evaluate response of patients with CD or UC to vedolizumab, stratified by disease duration. We analyzed data from a retrospective, multicenter, consortium of patients with CD (n = 650) or UC (n = 437) treated with vedolizumab from May 2014 through December 2016. Using time to event analyses, we compared rates of clinical remission, corticosteroid-free remission (CSFR), and endoscopic remission between patients with early-stage (≤2 years duration) and later-stage (>2 years) CD or UC. We used Cox proportional hazards models to identify factors associated with outcomes. Within 6 months initiation of treatment with vedolizumab, significantly higher proportions of patients with early-stage CD, vs later-stage CD, achieved clinical remission (38% vs 23%), CSFR (43% vs 14%), and endoscopic remission (29% vs 13%) (P < .05 for all comparisons). After adjusting for disease-related factors including previous exposure to TNF antagonists, patients with early-stage CD were significantly more likely than patients with later-stage CD to achieve clinical remission (adjusted hazard ratio [aHR], 1.59; 95% CI, 1.02-2.49), CSFR (aHR, 3.39; 95% CI, 1.66-6.92), and endoscopic remission (aHR, 1.90; 95% CI, 1.06-3.39). In contrast, disease duration was not a significant predictor of response among patients with UC. Patients with CD for 2 years or less are significantly more likely to achieve a complete response, CSFR, or endoscopic response to vedolizumab than patients with longer disease duration. Disease duration does not associate with response vedolizumab in patients with UC.

16 January 2018 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
DFD Faleck
D Faleck
PSP Shashi
P Shashi
JMJ Meserve
J Meserve
MRM Rahal
M Rahal
SKS Kadire
S Kadire
PDP S Dulai
P S Dulai
We aimed to compare the effectiveness of vedolizumab (VDZ) to tumour necrosis factor (TNF)-antagonist therapy for ulcerative colitis (UC). Using a multicentre, US-based consortium of UC patients treated with VDZ or TNF-antagonist therapy, we performed propensity score matching (1:1) accounting for age, sex, prior UC-related hospitalisation within the previous year, disease extent, disease severity, steroid refractoriness or dependence, and prior TNF-antagonist failure. Treatment response was categorised using the physician global assessment. Using Cox proportional hazard models, we compared cumulative rates of clinical remission (complete resolution of UC-related symptoms), steroid-free remission (on steroids at baseline, tapered off, no repeat steroid prescription for 4 weeks), and endoscopic healing (Mayo endoscopic subscore of 0 or 1). Hazard ratios (HRs) and 95% confidence intervals (CIs) are reported for VDZ compared with TNF-antagonist therapy. The propensity score model accurately predicted treatment status (area under curve 0.73). Of 646 UC patients, 334 were included after matching (n = 167 VDZ,; 49% male; median age 36 years). After adjusting for concomitant steroid use, concomitant immunomodulator (azathioprine, 6-mercaptopurine, methotrexate) use, and number of prior TNF-antagonists used, VDZ-treated patients had statistically significant higher 12-month cumulative rates of clinical remission (54% vs. 37%; HR 1.54, 95% CI 1.08–2.18) and endoscopic healing (50% vs. 42%, HR 1.73, 95% CI 1.10–2.73). Cumulative 12-month rates for steroid-free remission were numerically higher for VDZ-treated patients, but not statistically significant (49% vs. 38%; HR 1.43, 95% CI 0.79–2.60), These findings were consistent when stratified by disease extent and prior TNF-antagonist exposure. After accounting for measurable disease and patient-specific characteristics that may impact biologic effectiveness, we observed that VDZ-treated UC patients had significantly higher 12-month cumulative rates of clinical remission and endoscopic healing, and numerically higher steroid-free remission rates, when compared with TNF-antagonist–treated patients. Randomised controlled trial data are needed to confirm these findings. Statistical analyses were conducted at the University of California, San Diego. Research funding was provided in part by Takeda Pharmaceuticals U.S.A., Inc.

16 January 2018 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
MBM Bohm
M Bohm
SSS V Sagi
S V Sagi
MFM Fischer
M Fischer
SKS Kadire
S Kadire
GTG Tran
G Tran
PDP S Dulai
P S Dulai
We aimed to compare the effectiveness of vedolizumab (VDZ) to tumour necrosis factor (TNF)-antagonist therapy for Crohn’s disease (CD). Using a multicentre, US-based consortium of CD patients treated with VDZ or TNF-antagonist therapy, we performed propensity score matching (1:1) accounting for age, sex, prior CD-related hospitalisation within the previous year, stricturing or penetrating disease complication history, prior bowel surgery, disease severity, steroid refractoriness or dependence, and prior TNF-antagonist failure. Treatment response was categorised using the Physician Global Assessment. Using Cox proportional hazard models, we compared cumulative rates of clinical remission (complete resolution of CD-related symptoms), steroid-free remission (on steroids at baseline, tapered off, no repeat steroid prescription for 4 weeks), and endoscopic healing (absence of ulcers or erosions). Hazard ratios (HR) and 95% confidence intervals (CI) are reported for VDZ vs. TNF-antagonist therapy. The propensity score model accurately predicted treatment status (area under curve 0.80). Of 1122 CD patients, 538 were included after matching (n = 269 VDZ; 44% male; median age 35 years). After adjusting for concomitant steroid or immunomodulator use, disease location (isolated small bowel, ileocolonic, isolated colonic), and number of prior TNF-antagonists used, VDZ-treated patients had numerically, but not statistically significant higher 12-month cumulative rates for clinical remission (38% vs. 34%; HR 1.27, 95% CI 0.91–1.78) and steroid-free remission (26% vs. 18%; HR 1.75, 95% CI 0.90–3.43). VDZ-treated patients had significant higher 12-month cumulative rates for endoscopic healing (50% vs. 41%; HR 1.67, 95% CI 1.13–2.47). Among patients with colonic involvement, VDZ-treated patients had significantly higher rates of clinical remission, steroid-free remission, and endoscopic healing (Table 1). Vedolizumab vs. TNF-antagonist therapy in Crohn’s disease. Adjusted for concomitant steroid use, concomitant immunomodulator use, and number of prior TNF-antagonists used. Vedolizumab vs. TNF-antagonist therapy in Crohn’s disease. Adjusted for concomitant steroid use, concomitant immunomodulator use, and number of prior TNF-antagonists used. After accounting for measurable disease- and patient-specific characteristics that may affect biological effectiveness, VDZ-treated CD patients had numerically higher 12-month cumulative rates of clinical remission, steroid-free remission, and endoscopic healing than TNF-antagonist-treated patients. CD patients with colonic involvement were significantly more likely to respond to VDZ than to TNF-antagonist therapy. Randomised controlled trial data are needed to confirm these findings. Statistical analyses were conducted at the University of California, San Diego. Research funding was provided in part by Takeda Pharmaceuticals.

1 May 2018 in Gastroenterology
Verified
Journal Article
Closed access
DLDana J. Lukin
Dana J. Lukin
AWAaron Weiss
Aaron Weiss
SASatimai Aniwan
Satimai Aniwan
SKSiri Kadire
Siri Kadire
GTGloria Tran
Gloria Tran
PDParambir Dulai
Parambir Dulai

1 May 2018 in Gastroenterology
Verified
Journal Article
Closed access
DFDavid Faleck
David Faleck
PSPreeti Shashi
Preeti Shashi
JMJoseph Meserve
Joseph Meserve
MRMahmoud Rahal
Mahmoud Rahal
SKSiri Kadire
Siri Kadire
PDParambir Dulai
Parambir Dulai

1 May 2018 in Gastroenterology
Verified
Journal Article
Closed access
MBMatthew Bohm
Matthew Bohm
SSSashivar Sagi
Sashivar Sagi
MFMonika Fischer
Monika Fischer
SKSiri Kadire
Siri Kadire
GTGloria Tran
Gloria Tran
PDParambir Dulai
Parambir Dulai